Glepaglutide acetate

• CAT Number: I042376
• Molecular Formula: C199H329N53O57
• Molecular Weight: 4376.06
• Purity: ≥95%

Glepaglutide acetate (Cat No.: I042376) is a long-acting glucagon-like peptide-2 (GLP-2) analog designed to enhance intestinal growth and function. It promotes mucosal regeneration, improves nutrient absorption, and strengthens gut barrier integrity, making it especially valuable in treating short bowel syndrome (SBS). The acetate salt form improves peptide stability and solubility for clinical use. Glepaglutide is administered subcutaneously and has shown promise in reducing parenteral support requirements in SBS patients. It is under investigation for broader gastrointestinal and intestinal failure-related therapeutic applications.

Reference

[1]. Naimi RM, et al. a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363.
[Content Brief]

[2]. Janssen P, et al. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2013 Jan;37(1):18-36.
[Content Brief]

[3]. Jolanta Skarbaliene, et al. ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn’s Disease Model. Gastroenterology, 2011, 140(5): S519.